Immix Biopharma, Inc. 8-K

What Happened

• Immix Biopharma, Inc. filed an 8-K on May 29, 2026 reporting the final vote results from its May 22, 2026 Annual Meeting. Stockholders elected nine directors and ratified Crowe LLP as the company’s independent registered public accounting firm for 2026.

Key Details

• Directors elected (votes For / Withheld / Broker Non-Votes):
  • Ilya Rachman: 35,738,887 For; 121,893 Withheld; 6,445,684 Broker Non-Votes
  • Gabriel Morris: 34,353,302 For; 1,507,479 Withheld; 6,445,683 Broker Non-Votes
  • Jason Hsu: 35,844,812 For; 15,969 Withheld; 6,445,683 Broker Non-Votes
  • Magda Marquet: 35,731,188 For; 129,592 Withheld; 6,445,684 Broker Non-Votes
  • Helen C. Adams: 35,677,258 For; 183,522 Withheld; 6,445,684 Broker Non-Votes
  • Carey Ng: 35,840,860 For; 19,921 Withheld; 6,445,683 Broker Non-Votes
  • Jane Buchan: 35,731,346 For; 129,434 Withheld; 6,445,684 Broker Non-Votes
  • Yekaterina Chudnovsky: 35,749,420 For; 111,360 Withheld; 6,445,684 Broker Non-Votes
  • Nancy Chang: 35,744,455 For; 116,325 Withheld; 6,445,684 Broker Non-Votes
• Auditor ratification: Crowe LLP was ratified with 42,276,496 For, 11,526 Against, and 18,442 Abstentions; there were no broker non-votes reported for this proposal.

Why It Matters

• For investors, these results confirm the company’s board slate and auditor for 2026, which affect corporate governance and external financial oversight. The vote totals show strong support for most director nominees and clear ratification of Crowe LLP. The presence of several million broker non-votes on the director elections indicates a portion of shares were held by brokers or nominees who did not vote those proxies, which can affect the effective voting base for contested governance matters.